OneTouch honors those with diabetes by launching #SmallVictories campaign
Johnson & Johnson’s LifeScan brand, makers of OneTouch Verio Flex, plans to honors those across the country with diabetes by launching a new campaign. #SmallVictories will feature in-person surprises celebrating everyday lifestyle changes that have helped in moving forward with managing blood glucose. This new venture resulted from a new survey showing that while 83% of people living with Type 2 diabetes feel like they are working to make everyday lifestyles changes, more than a quarter cannot remember the last time they received any recognition for their efforts.
Overall, #SmallVictories aims to help people with diabetes see how the choices they make add up and empower them to celebrate each and every victory, the company said. As part of the campaign, the company will be surprising several people living with diabetes in front of a live audience with a personal party experience based on their unique small victory.
“As a doctor living with diabetes, I have the unique perspective of wearing both ‘patient’ and ‘physician’ hats,” Jeremy Pettus, an endocrinologist and assistant professor of medicine at the University of California, San Diego said. “One of the biggest differences is reinforcing the notion that small, everyday actions lead to sustainable wins. As a OneTouch Verio Flex system user, I’m happy to partner with a company that recognizes the power of positivity and creates a people-friendly meter that helps to encourage these behaviors.”
The OneTouch brand-sponsored survey of 1,036 people living with Type 2 diabetes found there is room for improvement in celebrating the small victories those living with diabetes make frequently:
- 48% of respondents stated they wish that they got some recognition for managing their diabetes;
- Nearly a third of respondents believed that their family and friends don’t know how hard they work to manage their diabetes;
- 44% of respondents agreed that managing diabetes is more stressful than their job/career; and
- 52% of those surveyed reported that if someone they cared about took the time to recognize their everyday effort it would motivate them to increase their efforts to live a healthier lifestyle.
“More than 30% of survey respondents said they make at least 10 decisions a day to manage their diabetes,” Dr. Brian Levy, Chief Medical Officer, LifeScan, said “We’ve designed our OneTouch Verio Flex meter and OneTouch Reveal mobile app to be an easy, seamless way for patients to log blood glucose readings, see blood glucose and activity timelines transformed into quick visual snapshots over days and weeks, and share their victories with their doctor, family and friends. Information is power, and we aim to empower people who use OneTouch products with the information they need to celebrate what’s working in their diabetes management plans.”
LifeScan is encouraging those in the diabetes community to share their #SmallVictories and recognize the #SmallVictories of others on social media by using the hashtag.
FDA approves Cipla’s generic Pulmicort Respules
The Food and Drug Administration has approved Cipla’s generic of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension). The drug is indicated as a maintenance treatment for asthma and as prophylactic therapy in children ages 12 months to 8 years. The Mumbai-based Cipla said the drug was available immediately for shipment.
Cipla’s generic will be available in dosage strengths of 0.25 mg/2 ml, 0.5 mg/2 ml and 1 mg/2ml. The product and its generics had U.S. sales of roughly $825 million for the 12 months ended September 2017, according to IQVIA data.
Cardinal Health kicks off Opioid Action Program
Cardinal Health has unveiled a big push to combat the opioid epidemic in the four Appalachian states that have been hit hardest by it. The Opioid Action plan is a pilot that officials at the Dublin, Ohio-based company said would bring front-line tools to first responders in Ohio, Kentucky, Tennessee and West Virginia, while increasing its investment in education.
“Opioid addiction and abuse has harmed too many people in our home state of Ohio, across Appalachia and around the country,” Cardinal Health chairman and CEO George Barrett said. “The men and woman of Cardinal Health are committed to being a part of the solution and we believe our Opioid Action Program will have a meaningful and positive impact.”
The program will see Cardinal Health purchasing roughly 80,000 doses of overdose reversal drug Narcan Nasal Spray or first responders and law enforcement officers. The company said it would also increase support for drug take-back and education programs, building on similar events held in 13 communities in the four states through the Cardinal Health Foundation’s partnership with the Ohio State University College of Pharmacy. The two organizations teamed up to create Generation Rx, an educational program about the dangers of prescription drug misuse.
“We have worked with the Cardinal Health Foundation to develop and expand Generation Rx and its educational materials and programming for nearly ten years,” Ohio State University College of Pharmacy professor Ken Hale said. “I am proud of the work we have done together to reach and educate people of all ages about the hazards of prescription drug misuse. The Opioid Action Program is a major expansion of the existing Generation Rx program and will enable our educational materials to reach even more people in communities that are fighting the opioid epidemic."
As part of the effort, Cardinal Health said it would invest $3 million in expanding grants for youth prevention efforts, as well as reduction and awareness efforts for prescribers and community responses. It will be partnering with the Alpert Medical School at Brown University to share medical school curricula addressing opioid misuse and treatment as part of a collaboration with medical schools nationwide.
“This program is intended to build on the important work we have done over the years to bring more resources to communities that need them, with a focus on known solutions that will help families and communities combat this epidemic,” Barrett said. “We look forward to partnering with other companies and organizations to leverage our commitment to help solve this complex public health crisis.”
Cardinal Health said it would evaluate the success and impact of the pilot and look to expand it into more states and communities.